Camber and Macleods voluntarily recall losartan tablets lots, after trace amounts of a possible carcinogen found in an API ingredient manufactured at the same third-party facility.
The FDA has announced that a lot of montelukast sodium tablets has been discovered to contain a different type of medicine, potentially posing health risks.